Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
HRS 25: The BIO-LIBRA Study
Author(s): Valentina Kutyifa Added: 10 months ago
HRS 2025 - Contemporary outcomes from implantable devices in non-ischemic cardiomyopathy patients observed more advanced heart failure symptoms in women at the time of ICD implantation, and white women implanted with CRT-D devices had significantly lower ventricular arrhythmia events compared to men of all races and black women implanted with both device types.Dr Valentina Kutyifa (University of… View more

Demographic

Electrophysiology & Arrhythmia
ESC HFA 25: SCD-PROTECT
Author(s): Johann Bauersachs Added: 9 months ago
ESC HF 25 - SCD-PROTECT shows high risk of sudden cardiac arrest (SCA) and sudden cardiac death (SCD) during early medical therapy optimization for reduced LVEF in patients with new non-ischemic cardiomyopathy or MI/CAD.Prof Johann Bauersachs (Hannover Medical School, Hannover, DE) discusses findings from the SCD–PROTECT study, an investigation of sudden cardiac arrest in patients with newly… View more

MI/ACS

Heart Failure
Erratum: Rehabilitation, Reverse Remodeling, and Cardiac Recovery
Added: 10 months ago

Intervention
Innovative Strategies in Ischemic Heart Disease Management
Author(s): Shrilla Banerjee , Mirvat Alasnag , Marta Kałuzna-Oleksy , et al Added: 1 year ago
In this video, Dr Marta Kałużna-Oleksy is joined by Dr Mirvat Alasnag, Dr Shrilla Banerjee and Dr Michal Hawranek to discuss strategies for heart failure management, based on a presentation at the Prevention and Intervention meeting in 2024.The faculty discuss SCAD, MINOCA and holistic approaches to managing these conditions, including lifestyle factors, hypertension and diabetes. They outline… View more

Heart Failure

Intervention
HFSA 25: The ATTRibute-CM Trial
Author(s): Ahmad Masri Added: 5 months ago
HFSA 2025 - Post hoc analysis of ATTRibute-CM reveals significant reduction in cardiovascular mortality and death after 30 months of acoramidis in patients with ATTR-CM.Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss a post hoc exploratory analysis from the ATTRibute-CM trial examining the timing and magnitude of cardiovascular outcome reductions with acoramidis in… View more

Heart Failure
Novel Therapies in ATTR-CM
Author(s): Michelle Dimza , Georgia Vasilakis , Justin L Grodin Added: 4 months ago

Heart Failure
ESC 23: ATTRibute-CM Trial
Author(s): Julian Gillmore Added: 2 years ago
ESC 2023 — Prof Julian Gillmore (University College London, UK) joins us onsite to discuss the findings of the ATTRibute-CM Study (NCT03860935). ATTRibute-CM was a randomised double-blind trial which aimed to evaluate the safety and efficacy of acoramidis in a cohort of patients diagnosed with transtherytin amyloid cardiomyopathy (ATTR-CM). 632 patients were enrolled in the trial, and were… View more

Heart Failure
Acoramidis Reduces Cumulative CV Events in ATTR-CM
Added: 2 weeks ago Source:  Radcliffe Cardiology
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease associated with a significant burden of recurrent cardiovascular (CV) events. A new post hoc analysis of the ATTRibute-CM trial suggests that acoramidis, an oral transthyretin (TTR) stabiliser, significantly reduces the cumulative burden of these outcomes.¹MethodologyThis exploratory analysis used data from the phase 3,… View more

Cardiovascular Renal Metabolic

Heart Failure
AHA 24: Nexiguran Ziclumeran for ATTR-CM
Author(s): Marianna Fontana Added: 1 year ago
AHA Conference 2024 - Safety and efficacy outcomes of nexiguran ziclumeran (NTLA-2001) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).Dr Marianna Fontana (University College London, London, UK) joins us onsite at AHA Conference to discuss the findings from the nexiguran ziclumeran for ATTR-CM trial (NCT04601051).Dr Fontana discusses a phase 1, ongoing, open-label, single… View more

Heart Failure
Cardiomyopathies: Management of Cardiomyopathies with Dr Michelle Kittleson
Author(s): Michelle Kittleson Added: 7 months ago
Learn about the management of HFrEF and HFpEF from Dr Michelle Kittleson (Cedars-Sinai Heart Institute, Los Angeles, US).This two-part video lecture series, part of Women As One's CLIMB® 2025 Skills Training Program, provides a comprehensive overview of key treatments and therapy approaches to cardiomyopathies.In this lecture, Dr Kittleson provides an in-depth review of the management of HFrEF… View more

Heart Failure